US EditionPublished • loading... • Updated
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
- A Phase Ib study of ASC30 oral tablet showed a mean body weight reduction of up to 6.5% compared to placebo, with mild-to-moderate gastrointestinal adverse events reported.
- The Phase Ib study of ASC30 subcutaneous injection revealed half-lives of 46 days for Injection A and 75 days for Injection B.
- The combination of ASC47 and ASC31 significantly outperformed tirzepatide and ASC31 monotherapy in promoting weight loss and muscle preservation in diet-induced obesity mouse studies.
- Presentations emphasized the promising efficacy and safety profiles of Ascletis' obesity pipeline and validated their Artificial Intelligence-Assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform technologies.
Insights by Ground AI
47 Articles
47 Articles
Kingsport Times-News+44 Reposted by 44 other sources
Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts.
The Herald JournalReposted by 
PR Newswire
PR NewswireLipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
SALT LAKE CITY, Nov. 4, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the presentation of a poster Treatment with Oral LPCN 2401,…
Coverage Details
Total News Sources47
Leaning Left3Leaning Right6Center12Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
14%
C 57%
R 29%
Factuality
To view factuality data please Upgrade to Premium
